Shenzhen Neptunus Bioengineering Co Ltd

Price Chart

Risk-Adjusted Performance

Shenzhen Neptunus Bioengineering Co Ltd (000078) Price Performance

Shenzhen Neptunus Bioengineering Co Ltd (000078) trades on SHE in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY3.77, down 3.58% from the previous close.

Over the past year, 000078 has traded between a low of CNY2.25 and a high of CNY5.29. The stock has gained 64.6% over this period. It is currently 28.7% below its 52-week high.

Shenzhen Neptunus Bioengineering Co Ltd has a market capitalization of $9.92B.

About Shenzhen Neptunus Bioengineering Co Ltd

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and offers value-added services for hospitals, medical institutions, and drug retail institutions and distributors. In addition, the company provides drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. It develops HW130 injection that completed the Phase I clinical trial for anti-tumor; and NEP018 for anti-tumor. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.

Compare Shenzhen Neptunus Bioengineering Co Ltd

Side-by-side comparison against top Healthcare peers.